Clinical Trials
74 trialsTherapy for Advanced NSCLC With EGFR 19delins Mutation
Fuzhou General Hospital
Bevacizumab Combined With Double Doses of Icotinib in Advanced NSCLC Patients With EGFR L858R Mutation
Tianjin Medical University Cancer Institute and Hospital
UPLIFT
The First Affiliated Hospital of Guangzhou Medical University
CORIN
Sun Yat-sen University
ICTAN
Sun Yat-sen University
Befotertinib and Icotinib in Treatment-naive Patients With Advanced EGFR-Mutant Lung Cancer
Betta Pharmaceuticals Co., Ltd.
IcomBine
Sun Yat-sen University
Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations
Betta Pharmaceuticals Co., Ltd.
A Multicenter Prospective Study to Assess the Effects of Adjuvant Icotinib in EGFRm Stage I NSCLC With High-risk of Disease Recurrence After Complete Resection
Peking University Cancer Hospital & Institute
ICAPE
Betta Pharmaceuticals Co., Ltd.
Neoadjuvant Icotinib With Chemotherapy for Epidermal Growth Factor Receptor(EGFR)-Mutated Resectable Lung Adenocarcinoma
Liaoning Cancer Hospital & Institute
NeoIpower
Peking University Cancer Hospital & Institute
Icotinib
Beijing Tiantan Hospital
EVIDENCE
Betta Pharmaceuticals Co., Ltd.
ALTER-L004
Tianjin Medical University Cancer Institute and Hospital
SAINT
Tianjin Medical University Cancer Institute and Hospital
Evaluation of Icotinib in Metastatic Triple-negative Breast Cancer After Second-line Therapy
Sun Yat-sen University
Alternating Icotinib and Chemotherapy for Advanced Non-small Cell Lung Cancer With EGFR Mutation
Henan Cancer Hospital
Cryotherapy Combine Icotinib for Advanced NSCLC Treatment
Fuda Cancer Hospital, Guangzhou
SMART
Betta Pharmaceuticals Co., Ltd.
Second-line Treatment With Icotinib in Esophageal Carcinoma Patients With EGFR Overexpression (IHC 3+) or Positive FISH
Betta Pharmaceuticals Co., Ltd.
Clinical Study of Combination Therapy With Ectiecinib, Pemetrexed and Platinum in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer With EGFR Mutations.
Tianjin Medical University Cancer Institute and Hospital
Adjuvant Chemotherapy With or Without Intercalated Icotinib
Nanfang Hospital, Southern Medical University
Clinical Study of Chinese Medicine Plus Targeted Therapy Maintenance in Advanced Pulmonary Adenocarcinoma
Shanghai University of Traditional Chinese Medicine
High Dose Icotinib With Sequential SRS For NSCLC Patients Harboring EGFR Mutation With Brain Metastases
Betta Pharmaceuticals Co., Ltd.
Anlotinib Hydrochloride Combined With EGFR TKIs in Advanced Non-small Cell Lung Cancer
The First Affiliated Hospital of Soochow University
Icotinib Combined With Radiation Therapy For NSCLC Patients With Brain Metastases and EGFR Mutation
Betta Pharmaceuticals Co., Ltd.
Icotinib as Neoadjuvant Therapy in EGFR-mutant Stage â…¢A-N2 Non-small Cell Lung Cancer
Betta Pharmaceuticals Co., Ltd.
Icotinib as Neoadjuvant and Adjuvant Therapy in EGFR-mutant Stage IIIB or Oligometastasis Non-small Cell Lung Cancer
Betta Pharmaceuticals Co., Ltd.
Icotinib as Consolidation Therapy After Chemoradiotherapy in EGFR-Mutant Stage IIIA-IIIB Non-small Cell Lung Cancer
Betta Pharmaceuticals Co., Ltd.
ICWIP
Betta Pharmaceuticals Co., Ltd.
Intermittent and Maintenance of Icotinib in Combination With Pemetrexed/Carboplatin Compared With Icotinib Single Drug in â…¢b/IV Non Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation
Sun Yat-sen University
Safety and Efficacy Study of Icotinib With Intensity-modulated Radiotherapy in Nasopharyngeal Carcinoma
Taizhou Hospital
CHALLENGE
Betta Pharmaceuticals Co., Ltd.
INCREASE
Betta Pharmaceuticals Co., Ltd.
Icotinib Combined With SBRT for Patients With Metastatic Non-squamous NSCLC With EGFR Mutation
Sichuan Cancer Hospital and Research Institute
Evaluation of the High Dose of Icotinib in Advanced Lung Cancer Patients After Failure of Target Therapy
Anhui Medical University
β-elemene Combine With EGFR-TKI for Advanced EGFR-TKI-resistant NSCLC
China Medical University, China
BRAIN
Guangdong Association of Clinical Trials
High-dose Icotinib Treatment Beyond Progression in EGFR Mutant NSCLC
ChineseAMS
Icotinib in Non-small Cell Lung Cancer Patients With Uncommon EGFR Mutation
ChineseAMS
First-line Icotinib With Concurrent Radiotherapy for NSCLC With EGFR Mutation
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
The Role of Icotinib in the Perioperative Treatment of IIIA - IIIB NSCLC Patients With EGFR Mutation
Beijing Haidian Hospital
Conmana Combined With Thalidomide to Treat NSCLC
Henan Provincial People's Hospital
RT Plus EGFR-TKI for Wild-type NSCLC
Hangzhou Cancer Hospital
TCL-1
Qilu Hospital of Shandong University
Phase II Study of Icotinib With Concurrent Radiotherapy in Elderly Patients With Esophageal Cancer
First People's Hospital of Hangzhou
First-line Treatment With Icotinib in Elder NSCLC EGFR Mutated Patients
Betta Pharmaceuticals Co., Ltd.
Icotinib in Combination With Chemotherapy Versus Chemotherapy Alone in Patients Progressed After Icotinib Treatment
Betta Pharmaceuticals Co., Ltd.
Neoadjuvant Therapy of Icotinib in Epidermal Growth Factor Receptor Mutated NSCLC Patients
Betta Pharmaceuticals Co., Ltd.